← Dashboard
Pipeline: Profile → Scout → Research → Draft → Applied

CARB-X 2026 Funding Portal

MODERATE Tx General
Strategy Notes
The venture's focus on predicting drug resistance mutations directly addresses AMR, a core CARB-X priority. The pre-seed stage and proof-of-concept validation align with CARB-X's early-stage funding, though the technology is computational rather than a traditional antibacterial product.
Key Materials
—
Your Notes
Status & Deadline
Status
INELIGIBLE
Deadline
rolling
Cycle
rolling
Amount
up to $2.5M
Type
grant
URL
Apply
Update Status
Log Application
AI Pipeline
Research Programme Generate Draft
Status History
2026-07-31 OPEN → INELIGIBLE · Programme closed on April 22, 2024, and the applicant's computational AMR prediction work does not align with the required product themes (direct-acting therapeutics for Gram-negative pathogens, target-based therapeutics for Novel Chemistry for AMR Challenge, non-vaccine neonatal sepsis prevention, or neonatal sepsis diagnostics).